SPC/PIL of the products can differ from this general indication.
1. Rheumatoid arthritis
Abatacept, in combination with methotrexate, is indicated for:
- the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.
- the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
2. Psoriatic Arthritis
Abatacept, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate and for whom additional systemic therapy for psoriatic skin lesions is not required.
North AmericaCanada (2)
United States (1)